Public Citizen Takes On Propoxyphene Again, This Time Comes Out On Top
The recent advisory committee review of the safety and efficacy of propoxyphene products left FDA with a quandary: the panel voted to remove propoxyphene-containing products from the market, citing little to no efficacy data, but also said their removal would be problematic
More from Archive
More from Pink Sheet
European pharma trade associations EFPIA and EUCOPE outline their respective views on how the EU’s pharma legislation overhaul should tackle antimicrobial resistance, and why transferable exclusivity vouchers alone will not suffice as incentives.
The Trump Administration requested a dismissal or transfer of a lawsuit seeking to tighten the safety requirements for the abortion pill mifepristone on procedural grounds, which still leaves the administration's position on the case's merits unclear.
Some advisory committee members said adding quantitative data on misuse, abuse, opioid use disorder and overdose to labeling would be helpful, but others worried the two epidemiological studies were not sufficiently generalizable to a broader population.